We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+17.77%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$516M
AUM Growth
+$170M
Cap. Flow
+$147M
Cap. Flow %
28.49%
Top 10 Hldgs %
81.88%
Holding
21
New
5
Increased
–
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
TTOO
T2 Biosystems, Inc
TTOO
+$47M
2
LOXO
Loxo Oncology, Inc
LOXO
+$44.8M
3
CTLT
CATALENT, INC.
CTLT
+$38.9M
4
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$12.2M
5
XENT
Intersect ENT, Inc
XENT
+$5.27M

Top Sells

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$55.7K

Sector Composition

Rank Sector Weight
1 Healthcare 72.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLTQ
1
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$58.8M 11.4%
2,597,742
– –
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$50.3M 9.75%
2,054,594
– –
TTOO
3
DELISTED
T2 Biosystems, Inc
TTOO
$45.6M 8.85%
+505
New +$47M
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$45.3M 8.79%
+3,452,493
New +$44.8M
CTLT
5
DELISTED
CATALENT, INC.
CTLT
$44.1M 8.55%
+1,761,225
New +$38.9M
CMRX
6
DELISTED
Chimerix, Inc.
CMRX
$42.1M 8.16%
1,522,943
– –
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
$37.9M 7.35%
332,428
– –
ASXC
8
DELISTED
Asensus Surgical, Inc.
ASXC
$36.3M 7.05%
641,217
– –
CEMP
9
DELISTED
Cempra, Inc.
CEMP
$36.1M 7%
3,293,060
– –
DRTX
10
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$25.7M 4.99%
2,030,175
– –
AMBI
11
DELISTED
Ambit Biosciences Corp
AMBI
$25.4M 4.93%
1,650,156
– –
AGRX
12
DELISTED
Agile Therapeutics
AGRX
$15.8M 3.07%
1,086
– –
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$15.4M 2.99%
201,000
– –
ROKA
14
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$11.3M 2.19%
+112,242
New +$12.2M
SRNE
15
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$7.97M 1.55%
1,763,500
– –
EVAR
16
DELISTED
Lombard Medical, Inc.
EVAR
$6.82M 1.32%
886,363
– –
XENT
17
DELISTED
Intersect ENT, Inc
XENT
$5.43M 1.05%
+350,000
New +$5.27M
LITS
18
Lite Strategy Inc
LITS
$35M
$5.26M 1.02%
38,090
-410
-1% -$55.7K
CEMP
19
CALL
DELISTED
Cempra, Inc.
CEMP
– –
-40,000
Closed -$429K
ZLTQ
20
CALL
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-43,261
Closed -$657K
PTX
21
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-1,000
Closed -$90K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Aisling Capital held 21 positions worth $516M, up 49% from $346M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Aisling Capital deployed $147M of net new capital in Q3 2014, opening 5 new positions. Its largest new stake was T2 Biosystems, Inc: 505 shares worth $45.6M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 76% a quarter earlier.

On the sell side, the largest reduction was Lite Strategy Inc, an estimated $55.7K trimmed.

  • Aisling Capital's largest Q3 2014 buy was T2 Biosystems, Inc: 505 shares worth $45.6M.
  • Aisling Capital's biggest Q3 2014 reduction was Lite Strategy Inc, cutting an estimated $55.7K.
  • Aisling Capital's ten largest holdings make up 82% of its $516M portfolio in Q3 2014.
  • Aisling Capital opened 5 new positions and closed 3 in Q3 2014.
  • Aisling Capital's portfolio value rose 49% quarter-over-quarter to $516M.

Based on Aisling Capital's 13F filing for Q3 2014, filed 13 Nov 2014.